OPKO Q3 Revenue Up 16% to $65.4M; Services Guidance Withdrawn Ahead of Labcorp Deal
OPK sits 71% above its 52-week low of $0.977.
Summary
OPKO reported Q3 continuing-operations revenue of $65.4 million, up 16%, with the operating loss narrowing to $31.4 million. It withdrew services guidance pending the Labcorp sale while issuing guidance for the remaining business.
Key Events · Earnings and Guidance · OPK
-
Q3 Continuing Revenue Up 16%
Revenue from continuing operations rose to $65.4 million from $56.4 million, driven by $5.8 million of Lilly mazdutide royalty revenue, Rayaldee growth to $8.6 million and about $3.0 million more from international operations.
-
Operating Loss Narrows to $31.4M
Consolidated operating loss improved to $31.4 million from $33.6 million. Global Products posted $6.0 million of segment operating income versus a $1.2 million loss, while Innovative Biotech's loss widened to $26.8 million on higher ModeX R&D.
-
Services Guidance Withdrawn
Citing uncertainty over the Labcorp closing timing, OPKO withdrew previously issued services revenue and total cost guidance. It now guides 2026 continuing-operations total revenue of $268 million to $278 million.
-
BioReference Recast as Discontinued
Following the September 30, 2026 board approval of the Labcorp sale, BioReference is reported as discontinued operations: Q3 revenue of $71.8 million and a loss of $18.0 million, versus a $54.6 million gain a year earlier that included a $101.6 million divestiture gain.
Analysis · OPK · Life Sciences
What matters here is the shape of the business that will remain after the $722 million Labcorp sale. In its first quarter with BioReference carved out as discontinued operations, OPKO posted continuing revenue of $65.4 million, up 16%, and a narrower operating loss of $31.4 million versus $33.6 million. The Global Products segment swung to $6.0 million of operating income from a $1.2 million loss, helped by $5.8 million of Lilly mazdutide royalty revenue and stronger Rayaldee and international sales. Against that, Innovative Biotech's loss widened to $26.8 million as ModeX spending rose, and the company pulled its services revenue and total cost guidance because the Labcorp closing timing is uncertain. With $403.2 million of cash and $84.3 million left on the buyback, near-term funding is less pressing than the closing of the lab sale and whether the remaining biopharma segments can approach breakeven.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $0.98 to $1.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.